A Phase II Study of Transarterial Chemoembolisation and Axitinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 05 Jul 2017 Planned End Date changed from 1 May 2017 to 31 May 2018.
- 05 Jul 2017 Planned primary completion date changed from 1 May 2017 to 31 May 2018.
- 10 Jun 2017 Biomarkers information updated